Latest Breaking News On - Williamh collier - Page 3 : comparemela.com

Arbutus to Report First Quarter 2022 Financial Results and Provide Corporate Update

WARMINSTER, Pa., April 21, 2022 Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target. | April 21, 2022

Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Moderna

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Arbutus Biopharma : Preliminary Data Shows that Arbutus' Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity - Form 8-K

Preliminary Data Shows that Arbutus Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity WARMINSTER, Pa., Dec. 01, 2021 . | December 1, 2021

Arbutus Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® 2021

WARMINSTER, Pa., Nov. 01, 2021 (GLOBE NEWSWIRE) Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused…

Arbutus Appoints Lisa M. Caperelli as Vice President, Investor Relations